With big pharma circling psychedelics, the next breakthrough may not come from tripping at all [Microdose]
Tuesday, September 16, 2025 1 min read
Key Takeaway: AbbVie has acquired Gilgamesh Pharmaceuticals for over $1 billion, signaling a significant shift in the biotech sector towards psychedelic-inspired drug development. This move reflects a growing belief in the potential of neuroplastogens, which are believed to help repair brain circuits affected by psychiatric conditions. The acquisition marks a pivotal moment for the integration of psychedelics into mainstream medicine.
Price reaction · baseline $11.2836 (2025-09-15 close) · hit pre-market · 3 other ENVB headline(s) in the window, move may be shared
day 0 close · peak
-2.7%
Market Sentiment Analysis
POSITIVE FACTORS
AbbVie's acquisition indicates growing confidence in psychedelic research.
The deal highlights the potential of neuroplastogens in treating psychiatric diseases.
Big pharma's interest may accelerate innovation in the psychedelic space.
Full Press Release Details
When AbbVie moved to acquire Gilgamesh Pharmaceuticals in a deal valued at more than $1 billion, it sent shockwaves through the biotech community. For years, psychedelic-inspired drug development has been viewed as a fringe pursuit, scientifically intriguing, but clinically and commercially fraught. AbbVie’s decision to pay up for access to Gilgamesh’s pipeline marked a clear shift: big pharma is officially buying into the promise of neuroplastogens, molecules that repair and rewire brain circuits disrupted in psychiatric disease.
Full Article >>
Frequently Asked Questions
What did AbbVie acquire?
AbbVie acquired Gilgamesh Pharmaceuticals for over $1 billion.
What are neuroplastogens?
Neuroplastogens are molecules that help repair and rewire brain circuits disrupted by psychiatric diseases.
Why is this acquisition significant?
It marks a shift in big pharma's interest in psychedelic-inspired drug development.
How does this affect the biotech community?
The acquisition signals growing confidence in the potential of psychedelics in medicine.